Showing results 1 to 1 of 1
| Title | Author(s) | Issue Date | |
|---|---|---|---|
KEYNOTE-495/KeyImPaCT, a randomized, phase 2, biomarker-directed trial of pembrolizumab-based therapy for non–small cell lung cancer (NSCLC) Proceeding/Conference:Annals of Oncology | 2019 |